Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?

Key Takeaways JNJ posted Q4 revenues of $24.56B, up 9.1%, with adjusted EPS of$ 2.46, rising 20.6% year over year.Innovative Medicines sales rose 10% to $15.76B, while MedTech climbed 7.5% to$ 8.8B despite Stelara LOE.J&J guided 2026 sales between $100B and$ 101B and EPS of $11.43-$ 11.63.Johnson & Johnson (JNJ) delivered strong fourth-quarter 2025 results, with both the top and bottom lines exceeding expectations. Total revenues rose 9.1% to $24.56 billion, while adjusted EPS of$ 2.46 rose 20.6% year over y ...